Interrater reliability of the assessment of disease activity by gastrointestinal ultrasound in a prospective cohort of patients with inflammatory bowel disease

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Rebecca L. Smith ◽  
Kirstin M. Taylor ◽  
Antony B. Friedman ◽  
Heidi Y. Su ◽  
Danny Con ◽  
...  
2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S269-S271
Author(s):  
R Smith ◽  
K Taylor ◽  
A Friedman ◽  
H Su ◽  
D Con ◽  
...  

Abstract Background Gastrointestinal ultrasound (GIUS) is an emerging modality in Australia for the assessment of disease activity in patients with inflammatory bowel disease (IBD). Its utility relies upon reproducibility of key indices, particularly when performed by different operators. Methods The aim of this article was to address the inter-rater reliability among GIUS-credentialed gastroenterologists in Australia, in their assessment of GIUS indices reflecting disease activity in patients with IBD. Methods Patients with IBD were prospectively recruited for paired, consecutive, blinded GIUS assessment at the commencement of a new medical therapy. GIUS was performed by two of four gastroenterologists accredited in GIUS at our centre. GIUS assessment was completed of the known disease distribution. Bowel wall thickness (BWT) was determined from a mean of four measurements for each segment of bowel examined. Colonic and small bowel BWT was defined as normal <3 mm, mild disease 3.1–6 mm, moderate disease 6.1–9 mm and severe disease >9.1 mm. Anastomotic BWT measures were considered as normal <5 mm or abnormal >5.1 mm. Colour Doppler assessment of the bowel wall was based on the Limberg scale1: no colour Doppler signal, mild, moderate and severe. The presence or absence of mesenteric hyperechogenicity surrounding each bowel segment and the presence or absence of reactive lymphadenopathy was assessed. The inter-rater reliability was tested with the Fleiss kappa. Results 26 patients were assessed. Sixty-nine per cent had a diagnosis of Crohn’s disease, 19% with ulcerative colitis and 12% with IBD unclassified. A total of 80 bowel segments were assessed. In the assessment of BWT, the observed agreement was 77.5% and the inter-rater reliability was in the substantial range with a Fleiss’ kappa of 0.63 (95% CI 0.48–0.78, p < 0.001). Of note, the percentage of BWT measures that differed by <1 mm, between each operator, was 79%. When assessing the degree of Doppler activity, the observed agreement was 82.5% and again inter-rater reliability in the substantial range with a Fleiss’ kappa of 0.68 (95% CI 0.54–0.83, p < 0.001). The assessment of mesenteric hyperechogenicity showed an observed agreement of 96.3%, with a near-perfect inter-rater agreement with a Fleiss’ kappa of 0.89 (95% CI 0.76–0.99, p < 0.001). For the presence or absence of lymphadenopathy, the observed agreement between users was 84.6% with a substantial inter-rater agreement reflected by a Fleiss’ kappa of 0.64 (95% CI 0.29–0.98, p < 0.001). Conclusion Among Gastroenterologists experienced and credentialed in GIUS, the inter-rater reliability of markers of intestinal inflammation was substantial, providing confidence in the reproducibility of findings between different operators.


2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S391-S393
Author(s):  
F de Voogd ◽  
H Joshi ◽  
E Van Wassenaer ◽  
G D’Haens ◽  
K Gecse

Abstract Background Disease activity during pregnancy in women with inflammatory bowel disease (IBD) is associated with miscarriage, preterm delivery and low birth weight. Monitoring disease activity throughout the pregnancy is therefore important. Gastrointestinal ultrasound (GIUS) has a high potential as a point-of-care tool for monitoring disease activity in IBD as it has been shown to correlate well with endoscopy and magnetic resonance imaging. However, data are scarce on the use of GIUS in IBD throughout pregnancy. The aim of this prospective study is to determine the feasibility and reliability of GIUS in pregnant IBD patients. Methods Patients were included when visiting the outpatient IBD pregnancy clinic. At each trimester, clinical and biochemical disease activity was evaluated and GIUS was performed. Feasibility was assessed by the ability to visualise each bowel segment (terminal ileum (TI), ascending (AC), transverse (TC), descending (DC) and sigmoid colon (SC)). Reliability was evaluated by using clinical and biochemical disease activity as a gold standard. This was defined as a Harvey–Bradshaw Index ≥4 in Crohn’s disease (CD) or a Simple Clinical Colitis Activity Index ≥5 in ulcerative colitis and a faecal calprotectin (FCP)³ 250 mg/g. Bowel wall thickness (BWT) of > 3 mm in the colon and > 2mm in the terminal ileum was considered as signs of active inflammation on ultrasound. A Mann–Whitney U-test and chi-square were used for statistical analysis. Results Thirty-two IBD patients (54% CD) were studied. Both a GIUS and FCP was available in 18, 11 and 6 patients for the first, second and third trimester, respectively. Eleven of 32 (34%) patients had clinically active disease at least at one time point during the pregnancy. Table 1 shows the visibility per segment. When the active disease was defined as an FCP ≥ 250 mg/g, GIUS could distinguish active from the non-active disease in the first, second and third trimester with a sensitivity of 80%, 75% and 75% and specificity of 85%, 86% and 100%, respectively. FCP levels were significantly higher in patients with an active disease on GIUS regardless of the trimester (mean 1095.5 ± 1453.8 mg/g vs. 265.25 ± 649.8 mg/g, p < 0.0001). Conclusion GIUS is accurate to distinguish active from the quiescent disease in pregnancy. Feasibility to visualise the TI and the SC decreased during the second and third trimester, although active disease could still be detected. Consequently, GIUS is feasible and reliable to assess disease activity throughout pregnancy in IBD.


BMJ ◽  
1983 ◽  
Vol 287 (6407) ◽  
pp. 1751-1753 ◽  
Author(s):  
S H Saverymuttu ◽  
J P Lavender ◽  
H J Hodgson ◽  
V S Chadwick

Sign in / Sign up

Export Citation Format

Share Document